Candel Therapeutics Inc (CADL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $486.37M
Last updated: Nov 17, 2026 at 11:04 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 39.6% below its 50-day moving average, and the 50-day average is above the 200-day average. The 14-day RSI is 29.2, below 30, the oversold line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about CADL
GNG News
All CADL news- CADLCandel Therapeutics (CADL) ratings reaffirmed by 4 firms after its earnings report
- CADL3 firms maintain Candel Therapeutics (CADL) ratings following its earnings report
- CADLCandel Therapeutics (CADL) receives Buy upgrade from B of A Securities
UpdatedHistorical
- CADLJefferies initiates coverage of Candel Therapeutics (CADL) at Buy
UpdatedHistorical
News
CADL Valuation
Candel Therapeutics (CADL) trades at 43.5x forward earnings.
- Forward P/E
- 43.5x
- P/FCF
- -6.4x
- P/B
- 3.4x
CADL Profitability: Margins, ROIC and FCF
Candel Therapeutics (CADL) has an operating margin of 0.0% and a net margin of 0.0%. It posts -43.5% ROIC.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROIC
- -43.5%
- ROE
- -93.6%
- FCF yield
- -15.6%
Candel Therapeutics Competitors
The companies most similar to Candel Therapeutics (CADL) include CytomX Therapeutics, Century Therapeutics and Indaptus Therapeutics.
Sector: Healthcare
Companies most similar to Candel TherapeuticsCADL Analyst Ratings
Candel Therapeutics (CADL) has a Buy consensus from 10 analysts: 10 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 10
- Strong Buy
- 0
- Buy
- 10
- Hold
- 0
- Sell
- 0
- Strong Sell
- 0
CADL Bull Case vs Bear Case
Bull case
- 100.0% of CADL's analyst ratings are Buy or Strong Buy.
Bear case
- CADL beat EPS estimates in 37.5% of its last 8 reported quarters.
CADL Earnings: Beat Rate and Next Report
Candel Therapeutics (CADL) beat the EPS estimate in 3 of the last 8 quarters (37.5%). Its next report is expected on Mar 10, 2027.
- Beat rate
- 3 of 8 quarters (37.5%)
- Average surprise
- -8.1%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.38
CADL Earnings Date
CADL reports Mar 10, 2027. The date is estimated.
CADL ETF Holders
GNG tracks 10 ETFs that hold CADL. The largest weights:
- State Street SPDR S&P Biotech ETF (XBI), 0.19% of the fund
- iShares Biotechnology ETF (IBB), 0.03% of the fund
- Fidelity Growth Company Fund (FDGRX), 0.01% of the fund
- iShares Russell 2000 ETF (IWM), 0.01% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
Updated Nov 12, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About CADL
When does CADL report earnings?
Candel Therapeutics Inc (CADL) is expected to report earnings on Mar 10, 2027.
Does CADL pay dividends?
Candel Therapeutics Inc (CADL) does not currently pay a regular dividend.
What is CADL's market cap?
Candel Therapeutics Inc (CADL) has a market capitalization of $486.37M with a current stock price of $5.81.
CADL pages: Overview, Earnings, Forecast, Financials, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.